Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LV-Visio-AMTRIX for Trophic Corneal Ulcers
NCT05172349Phase 2Withdrawn
- Sponsor
- TBF Génie Tissulaire
- Start
- Apr 2022
- Primary completion
- Sep 2022
- Modality
- Device-based Delivery, Tissue Cells
01
Overview
Phase 2, open-label, single-arm trial of LV-Visio-AMTRIX in corneal ulcer and persistent corneal epithelial defect (PED), sponsored by TBF Génie Tissulaire. Primary endpoint: Largest diameter of persistent epithelial lesion area or corneal ulcer under 0.5 mm at 15 days. Planned start Apr 2022; status: withdrawn.
02
Drugs
LV-Visio-AMTRIX
03
Conditions
corneal ulcerpersistent corneal epithelial defect (PED)
Beyond the preview
Go deeper on NCT05172349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05172349.